These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 9862844

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES.
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [Abstract] [Full Text] [Related]

  • 6. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF.
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [Abstract] [Full Text] [Related]

  • 7. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid.
    Boberg KM, Wisløff T, Kjøllesdal KS, Støvring H, Kristiansen IS.
    Aliment Pharmacol Ther; 2013 Oct; 38(7):794-803. PubMed ID: 23915021
    [Abstract] [Full Text] [Related]

  • 8. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD.
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM, Schrumpf E.
    Tidsskr Nor Laegeforen; 1997 Sep 30; 117(23):3370-3. PubMed ID: 9411890
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.
    Poupon RE, Poupon R, Balkau B.
    N Engl J Med; 1994 May 12; 330(19):1342-7. PubMed ID: 8152446
    [Abstract] [Full Text] [Related]

  • 12. The natural history of PBC: has it changed?
    Lee YM, Kaplan MM.
    Semin Liver Dis; 2005 Aug 12; 25(3):321-6. PubMed ID: 16143947
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial.
    Papatheodoridis GV, Hadziyannis ES, Deutsch M, Hadziyannis SJ.
    Am J Gastroenterol; 2002 Aug 12; 97(8):2063-70. PubMed ID: 12190178
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD.
    Hepatology; 2000 Feb 12; 31(2):318-23. PubMed ID: 10655252
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon RE, Poupon R.
    Liver Int; 2004 Jun 12; 24(3):187-93. PubMed ID: 15189267
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.